Free shipping on all orders over $ 500

Histamine Receptor Histamine Receptor

Cat.No.  Name Information
M20515 Emedastine Emedastine is a potent, high affinity histamine H1-receptor-selective antagonist with Ki of 1.3 ±0.1 nM for H1-receptors while considerably weaker at H2- (K1 = 49,067 ± 11,113 nM) and H3-receptors (Ki = 12,430 ± 1,282 nM).
M20511 Betahistine Betahistine Dihydrochloride is a histamine H3 receptors inhibitor used as an antivertigo drug.
M20495 Cloperastine hydrochloride Cloperastine is a drug with a central antitussive effect, and is also endowed with an antihistaminic activity.
M20424 CarbinoxaMine Maleate Carbinoxamine maleate is a histamine-H1 receptor blocking agent with antihistamine and anticholinergic properties.
M13995 Adriforant hydrochloride Adriforant hydrochloride (PF-3893787 hydrochloride) is a novel histamine H4 receptor antagonist binding affinity (Ki=2.4 nM) and is also a functional (Ki=1.56 nM) antagonist.
M13994 N-Acetylhistamine N-Acetylhistamine is a histamine metabolite. N-acetylhistamine can be used as a potential biomarker of histidine metabolism for anaphylactoid reactions.
M13992 Chlorcyclizine hydrochloride Chlorcyclizine hydrochloride is a histamine H1 antagonist.
M13991 Bepotastine Bepotastine is a selective and orally active second-generation histamine H1 receptor antagonist. Bepotastine has the potential for allergic rhinitis, allergic conjunctivitis and urticaria/pruritus research.
M11287 JNJ-39758979 Jnj-39758979 is a selective, orally active, high-affinity histamine H4 receptor antagonist with Ki values of 12.5, 5.3 and 25 nM for human, mouse and monkey histamine H4 receptor, respectively. Jnj-39758979 antagonized histamine-induced cAMP inhibition with a pA2 of 7.9. Jnj-39758979 has good anti-inflammatory and antipruritic effects.
M10773 ABT-239 ABT-239 is a novel, highly effective, non-imidazole H3R antagonist and antagonist of TRPV1.




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.